A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

NCT03776071 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

260

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma

Interventions

DRUG: Enzastaurin Hydrochloride
OTHER: Placebo
DRUG: Temozolomide
RADIATION: Radiotherapy

Sponsor

Denovo Biopharma LLC